Congress President of APASL 2025 BEIJING
Dr. Lai Wei from Beijing Tsinghua Changgung Hospital, highlights the key features of this year’s conference:
Dr. Lai Wei: Currently, two-thirds of global viral hepatitis cases are concentrated in Asia, with about half occurring in China. The World Health Organization (WHO) aims to reduce new viral hepatitis infections by 90% and related mortality by 65% by 2030. Thus, contributions from the Asia-Pacific region are pivotal in achieving these elimination goals.To address this, the conference will host a Virus Elimination Forum, focusing on integrating public health prevention with clinical practice and sharing the remarkable achievements of the Asia-Pacific region, in viral hepatitis prevention and treatment. The forum will collaborate closely with the WHO to delve into regional experiences and roadmaps for the elimination of hepatitis.
Multidisciplinary collaboration stands as a core theme. Combating viral hepatitis requires expertise beyond hepatology, spanning public health, hepatobiliary surgery, transplantation, oncology, and more. The Multidisciplinary Collaboration Forum will unite specialists across disciplines to discuss holistic, end-to-end patient care—from prevention and diagnosis to advanced treatments, including post-hepatocellular carcinoma (HCC) chemotherapy, targeted therapy, and surgery. Nursing experts will also contribute insights to enhance patient care standards.
Another focus is “cure” . The Functional Cure Forum will emphasize breakthroughs in achieving functional cure for hepatitis B, which could alleviate public health burdens, reduce social stigma, and lower patient costs. New consensus guidelines on the functional cure of hepatitis B will be unveiled to steer clinical practice.
The conference also underscores the critical role of female leadership in hepatology, exploring ways to empower women in this field. While progress has been made in some Asia-Pacific countries, female representation in liver disease management remains limited. Sessions will share successful models from the region to improve care for female patients, particularly in maternal-fetal hepatitis prevention, pregnancy-related liver disorders, and primary biliary cholangitis.
Compared to previous editions, APASL 2025 highlights more research led by Asia-Pacific scholars. The Late Breaker Session features nine pivotal reports, three of which focus on viral hepatitis, showcasing the Asia-Pacific region’s groundbreaking contributions. The agenda also spotlights advances in HCC research, given the profound societal impact of hepatitis and liver cancer. The conference structure reflects China’s distinctive achievements under the leadership of the Communist Party of China.
APASL 2025 Detailed Agenda Now Live!
Official Website: https://www.apasl2025beijing.com/
Access Path: Homepage → Programs → Daily Scientific Program (Tentative)
Hepatology Digest will provide comprehensive real-time coverage of this academic milestone. Join us in witnessing a new era of collaboration and innovation in liver disease management!
